Walvax Biotechnology Co., Ltd.

SZSE:300142.SZ

21.88 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 4,081.7465,086.4453,462.8312,939.0211,121.22879.045668.265591.0051,006.027719.021583.095537.559473.811358.792239.13184.062129.362
Cost of Revenue 683.766609.469394.339399.81227.098172.34215.344280.719574.904406.956161.63463.91641.89632.72132.61238.963.254
Gross Profit 3,397.984,476.9763,068.4922,539.212894.122706.705452.921310.286431.123312.065421.461473.643431.915326.071206.518145.16266.108
Gross Profit Ratio 0.8320.880.8860.8640.7970.8040.6780.5250.4290.4340.7230.8810.9120.9090.8640.7890.511
Reseach & Development Expenses 738.039932.895621.493176.49364.81125.48499.007107.986136.34796.36227.4528.90133.55318.524000
General & Administrative Expenses 96.405100.094159.939134.845119.98554.07823.48338.944147.74476.07249.21727.37917.13213.6731.86729.28430.194
Selling & Marketing Expenses 1,519.5762,025.6481,330.9891,130.196499.129349.463253.678150.366208.174187.472104.336122.699144.17991.59961.10770.56626.271
SG&A 1,830.7922,125.7421,490.9291,265.041619.114403.541277.161189.31355.919263.544153.553150.077161.312105.26992.97499.8556.465
Other Expenses -165.07686.58589.58176.31546.014-61.78-432.506195.41219.17211.8076.833-17.576-28.75513.5785.09312.2765.014
Operating Expenses 2,733.9073,145.2212,202.0021,517.849729.938601.686431.804407.119588.587502.221343.988232.484225.216146.8495.234102.43558.51
Operating Income 664.0731,099.44967.5281,055.08232.8841,245.279-144.154-160.357-898.165128.1613.508253.894237.977173.41789.16735.1645.549
Operating Income Ratio 0.1630.2160.2790.3590.2081.417-0.216-0.271-0.8930.1780.0060.4720.5020.4830.3730.1910.043
Total Other Income Expenses Net -65.479-28.975-258.583318.224-3.4231,078.481-597.777131.517-727.216328.113-67.17226.30839.2093.956-17.0840.5831.859
Income Before Tax 598.5941,070.465708.9451,373.304229.4611,183.499-576.65934.684-884.68137.95710.301267.467245.907183.18794.19943.319.457
Income Before Tax Ratio 0.1470.210.2050.4670.2051.346-0.8630.059-0.8790.1920.0180.4980.5190.5110.3940.2350.073
Income Tax Expense 87.651132.239107.593162.11735.325120.808-18.4174.66439.97241.2525.41942.10938.3728.7717.8688.612.033
Net Income 419.39728.652601.3521,003.187194.1361,046.204-537.13770.459-840.895143.42547.893232.803207.538154.41776.33134.77.425
Net Income Ratio 0.1030.1430.1740.3410.1731.19-0.8040.119-0.8360.1990.0820.4330.4380.430.3190.1890.057
EPS 0.260.460.380.650.130.68-0.350.05-0.60.10.0330.170.150.140.0730.0550.079
EPS Diluted 0.260.450.380.650.130.68-0.350.05-0.60.10.0330.170.150.140.0730.0550.079
EBITDA 997.4091,649.5971,111.3651,179.028277.4131,376.386-269.834292.175-51.711515.687234.559334.324277.223201.286116.27261.05714.583
EBITDA Ratio 0.2440.3240.3210.4010.2471.566-0.4040.494-0.0510.7170.4020.6220.5850.5610.4860.3320.113